Other languages Propanc Biopharma, Inc.

Equities

PPCB

US74346N6022

Market Closed - OTC Markets Other stock markets 03:33:15 2024-07-12 pm EDT			5-day change	1st Jan Change
0.00075 ^USD	-10.71%		-20.00%	-93.33%

Jun. 25	Propanc Biopharma, Inc. Receives Certificate of Grant for "Proenzymes Composition" Patent from Japanese Patent Office	CI
Jun. 20	Propanc Biopharma, Inc. announced that it has received $0.03375 million in funding	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Propanc Biopharma, Inc. Receives Certificate of Grant for "Proenzymes Composition" Patent from Japanese Patent Office	Jun. 25
Propanc Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	May. 15
Propanc Biopharma, Inc. Receives Certificate of Grant for ?Composition of Proenzymes for Cancer Treatment? Patent from European Patent Office	Apr. 16
Propanc Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 20
Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office	Jan. 16
Propanc Biopharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 14
Propanc Biopharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-28
Propanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, Australia	23-08-15
Propanc Biopharma, Inc. Produces Synthetic Recombinant Proenzymes for Cancer Therapy Targeting Advanced Solid Tumors	23-07-05
Propanc Biopharma, Inc. Announces Strategic Pharma Partnering Initiative	23-06-06
Propanc Biopharma, Inc.'s Intellectual Property Portfolio Makes Important Advancements in Europe	23-05-25
Propanc Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-15
Propanc Biopharma, Inc. Announces That PRP Suppresses TGF-b Pathway & Tumor Microenvironment in Pancreatic Cancer	23-03-28
Propanc Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-10
Propanc Biopharma’s CSO Predicts PRP Could Enhance Therapeutic Effects of Immune Checkpoint Therapy for Pancreatic Cancer	22-11-15
Propanc Biopharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	22-11-14
Propanc Biopharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2022	22-09-28
Propanc Biopharma, Inc. Auditor Raises 'Going Concern' Doubt	22-09-27
Propanc Biopharma, Inc. Synthesizes Recombinant Trypsinogen & Chymotrypsinogen Via Proenzyme Optimization Project Joint Research & Drug Discovery Program	22-08-23
Propanc Biopharma Receives Notice of Allowance for Proenzyme Compositions to Treat Cancer from the European Patent Office	22-08-16

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Propanc Biopharma, Inc.

Equities

PPCB

US74346N6022

Other languages

Filters